Tzu-I Chao

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells

Chun‐Yu Liu, Tzu‐Ting Huang, Pei‐Yi Chu et al. · Experimental & Molecular Medicine · 2017 · 39 citations · Full text

Breast Oncology, Apoptosis, Cell Death +18

A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy

Tzu-I Chao, Wei‐Tien Tai, Man‐Hsin Hung et al. · Cancer Letters · 2015 · 32 citations

Hepatology, Medicine, Liver Cancer +5

Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells

Chun‐Yu Liu, Kuen‐Feng Chen, Tzu-I Chao et al. · Journal of Molecular Medicine · 2017 · 24 citations

P-stat3 Signaling, Sequential Combination, Medicine +8

TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1

Chi-Ting Shih, Chung-Wai Shiau, Yen‐Lin Chen et al. · Cancer Letters · 2020 · 24 citations

Novel Erlotinib Derivative, Tumor-associated Macrophages, Medicine +8

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma

Ming-Hung Hu, Li-Ju Chen, Yen‐Lin Chen et al. · Oncotarget · 2017 · 20 citations · Full text